Hua Medicine
HKEX:2552
Hua Medicine
Cost of Revenue
Hua Medicine
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
H
|
Hua Medicine
HKEX:2552
|
Cost of Revenue
-ÂĄ67.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cost of Revenue
-ÂĄ1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cost of Revenue
-ÂĄ6.1B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-24%
|
||
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cost of Revenue
-ÂĄ3.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-11%
|
||
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cost of Revenue
-ÂĄ28.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
||
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cost of Revenue
-ÂĄ242.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Hua Medicine
Glance View
Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.
See Also
What is Hua Medicine's Cost of Revenue?
Cost of Revenue
-67.9m
CNY
Based on the financial report for Jun 30, 2024, Hua Medicine's Cost of Revenue amounts to -67.9m CNY.
What is Hua Medicine's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-87%
Over the last year, the Cost of Revenue growth was -87%.